Dec 03, 2019 / 04:45PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Okay. So thank you all for being here. Anirvan, thank you for making time. Just to level set for everyone. I was talking to Joe and the Biogen team, and most of the folks on the Biogen side have flown out to CTAD. So first of all, thank you for -- Biogen for still making time. Thank you, Anirvan, for coming up.
Questions and Answers:
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity ResearchBefore we kick things off, Anirvan, since many of the investors on the street haven't had a chance to get to know you. Can you just tell us your role at the company, your background and also to level set how much we can or can't talk about aducanumab on this session?
Anirvan Ghosh - Biogen Inc. - SVP of Research and Early Development
Sure. Thanks for having me here. So just a couple of things. First of all, I might be making some forward-looking
Trustpilot
